TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 17, No. 4 February 15, 2011
(The next issue will be on March 1, 2011)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PRODUCT ANNOUNCEMENT
The Asserachrom® VIIa-AT product from Diagnostica Stago, Inc. (catalog #00491) is a new kit for the analysis of plasma circulating factor VIIa-antithrombin (FVIIa-AT) complex levels by the ELISA method, and can be run on any plate reader reporting at 450 nm. The kit is labeled for research use only, not for use in diagnostic procedures worldwide. This new product, the first of its kind is useful for looking at FVIIa-AT, and thus coagulation activation in prothrombotic disease states such as arterial and veneous thrombosis.
Unlike the FVIIa-TFPI complex, which stays bound to the endothelium, FVIIa-AT is released into the blood upon coagulation activation, making it a useful marker for this phenomenon. Use of this kit has been reported using plasmas from research subjects exhibiting hypercoagulability as a result of hemotological neoplasia (1) as well as factor VII deficiency (2). In addition, samples from patients on oral anticoagulation were examined using this kit (2). Other studies have also shown elevation of FVIIa-AT in antiphospholipid syndrome (3) and recent myocardial infarction (4).
For more information, please contact Paul Riley, PhD; 973-631-1200 x4238, (paul DOT riley AT stago-us DOT com).
1. H. F. Negaard et al., Thromb Haemost 99, 1040 (Jun, 2008).
2. L. Spiezia et al., Thromb Haemost 103, 1188 (Jun, 2010).
3. R. A. S. Roubey, T. Lovell, J. H. Morrissey, J. Thromb. Haemostasis 5, Abstract from the XXIst Congress of the ISTH (2007).
4. A. Silveira et al., J. Thromb. Haemostasis 5, Abstract from the XXIst Congress of the ISTH (2007).
DISCLAIMER: Commercial product announcements appearing in TRIGGER are provided "as is" for informational purposes only. The editors of TRIGGER have not necessarily evaluated any materials from commercial suppliers described in this newsletter or on its web sites, and we certainly are not endorsing any specific suppliers or products. Furthermore, the editors receive no revenues from any source in the course of publishing TRIGGER.
__________________________________________________________
PAPERS IN PRESS
None submitted for this issue.
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1hSOFnEHt3QvVFLxFWGkaMI/
Arellano-Rodrigo E (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:574-575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306249
Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A, McCarty OJ (2011) Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 8:015014.
http://www.ncbi.nlm.nih.gov/pubmed/21301066
Collier ME, Ettelaie C (2011) Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem.
http://www.ncbi.nlm.nih.gov/pubmed/21310953
Emekli-Alturfan E, Basar I, Malali E, Elemek E, Oktay S, Ayan F, . . . Noyan U (2011) Plasma Tissue Factor Levels and Salivary Tissue Factor Activities of Periodontitis Patients with and without Cardiovascular Disease. Pathophysiol Haemost Thromb.
http://www.ncbi.nlm.nih.gov/pubmed/21293108
Franchini M, Targher G, Lippi G (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306247
Gavins FN, Russell J, Senchenkova EL, De Almeida Paula L, Damazo AS, Esmon CT, . . . Granger DN(2011) Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood.
http://www.ncbi.nlm.nih.gov/pubmed/21304105
Gidaris D, Economou M, Valeri R, Gombakis N, Athanasiou-Metaxa M (2010) Successful treatment of a spontaneous haemothorax with recombinant factor VIIa in a haemophilic child with inhibitors. Hippokratia 14:289-290.
http://www.ncbi.nlm.nih.gov/pubmed/21311642
Gustafson EK, Elgue G, Hughes RD, Mitry RR, Sanchez J, Haglund U, . . . Nilsson B (2011) The Instant Blood-Mediated Inflammatory Reaction Characterized in Hepatocyte Transplantation. Transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/21289595
Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM (2011) Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost.
http://www.ncbi.nlm.nih.gov/pubmed/21294824
Jenabali Jahromi B, Karimi M (2011) Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency. Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21299748
Jiang W, Kou J, Yuan S, Sun L, Yu B (2011) A Simplified and High-Throughput Chromogenic Assay for Testing Tissue Factor-Dependent Procoagulant Activity. J Biomol Screen.
http://www.ncbi.nlm.nih.gov/pubmed/21310849
Jin Y, Wang M, Niu Z, Xie Y, Xie H, Yang L (2011) [An inherited coagulation factor VII deficiency pedigree caused by homozygous mutation of His348Gln.]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28:10-13.
http://www.ncbi.nlm.nih.gov/pubmed/21287501
Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, Trenk D (2011) High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg.
http://www.ncbi.nlm.nih.gov/pubmed/21295991
Koci J, Dedek T, Havel E, Trlica J (2011) Recombinant Activated Factor VII-"Lifesaving or Surgeon Correcting"? J Trauma 70:523-524.
http://www.ncbi.nlm.nih.gov/pubmed/21307759
Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Osterud B, Sandset PM, Iversen PO (2011) Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul Fibrinolysis.
http://www.ncbi.nlm.nih.gov/pubmed/21297449
Marzano AV, Tedeschi A, Rossio R, Fanoni D, Cugno M (2010) Prothrombotic state in Churg-Strauss syndrome: a case report. J Investig Allergol Clin Immunol 20:616-619.
http://www.ncbi.nlm.nih.gov/pubmed/21314005
Mazer CD, Leong-Poi H, Chhina T, Alfardan Z, Lapierre H, Wang Z, . . . Teitel J (2011) Recombinant factor VIIa affects anastomotic patency of vascular grafts in a rabbit model. J Thorac Cardiovasc Surg.
http://www.ncbi.nlm.nih.gov/pubmed/21281943
Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL (2011) Exposure and safety of higher doses of recombinant factor VIIa >/=250 mug kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21299750
Patel A, Cooper N, Laffan MA (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:574; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306250
Potzsch B, Ivaskevicius V (2011) Haemostasis management of massive bleeding. Hamostaseologie 31:15-20.
http://www.ncbi.nlm.nih.gov/pubmed/21311819
Regnault V, Perret-Guillaume C, Kearney-Schwartz A, Max JP, Labat C, Louis H, . . . Lacolley P (2011) Tissue Factor Pathway Inhibitor: A New Link Among Arterial Stiffness, Pulse Pressure, and Coagulation in Postmenopausal Women. Arterioscler Thromb Vasc Biol.
http://www.ncbi.nlm.nih.gov/pubmed/21293010
Shing CM, Adams MJ, Fassett RG, Coombes JS (2011) Nutritional compounds influence tissue factor expression and inflammation of chronic kidney disease patients in vitro. Nutrition.
http://www.ncbi.nlm.nih.gov/pubmed/21295946
Valentino LA, Cooper DL, Goldstein B (2011) Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21294815
Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, . . . Opal S (2011) Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med.
http://www.ncbi.nlm.nih.gov/pubmed/21297074
Yank V, Stafford RS (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306248
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 17, No. 4 February 15, 2011
(The next issue will be on March 1, 2011)
__________________________________________________________
TRIGGER is also available by RSS Feed:
http://feeds.feedburner.com/blogspot/glro
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PRODUCT ANNOUNCEMENT
Unlike the FVIIa-TFPI complex, which stays bound to the endothelium, FVIIa-AT is released into the blood upon coagulation activation, making it a useful marker for this phenomenon. Use of this kit has been reported using plasmas from research subjects exhibiting hypercoagulability as a result of hemotological neoplasia (1) as well as factor VII deficiency (2). In addition, samples from patients on oral anticoagulation were examined using this kit (2). Other studies have also shown elevation of FVIIa-AT in antiphospholipid syndrome (3) and recent myocardial infarction (4).
For more information, please contact Paul Riley, PhD; 973-631-1200 x4238, (paul DOT riley AT stago-us DOT com).
1. H. F. Negaard et al., Thromb Haemost 99, 1040 (Jun, 2008).
2. L. Spiezia et al., Thromb Haemost 103, 1188 (Jun, 2010).
3. R. A. S. Roubey, T. Lovell, J. H. Morrissey, J. Thromb. Haemostasis 5, Abstract from the XXIst Congress of the ISTH (2007).
4. A. Silveira et al., J. Thromb. Haemostasis 5, Abstract from the XXIst Congress of the ISTH (2007).
DISCLAIMER: Commercial product announcements appearing in TRIGGER are provided "as is" for informational purposes only. The editors of TRIGGER have not necessarily evaluated any materials from commercial suppliers described in this newsletter or on its web sites, and we certainly are not endorsing any specific suppliers or products. Furthermore, the editors receive no revenues from any source in the course of publishing TRIGGER.
__________________________________________________________
PAPERS IN PRESS
None submitted for this issue.
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1hSOFnEHt3QvVFLxFWGkaMI/
Arellano-Rodrigo E (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:574-575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306249
Berny-Lang MA, Aslan JE, Tormoen GW, Patel IA, Bock PE, Gruber A, McCarty OJ (2011) Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 8:015014.
http://www.ncbi.nlm.nih.gov/pubmed/21301066
Collier ME, Ettelaie C (2011) Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J Biol Chem.
http://www.ncbi.nlm.nih.gov/pubmed/21310953
Emekli-Alturfan E, Basar I, Malali E, Elemek E, Oktay S, Ayan F, . . . Noyan U (2011) Plasma Tissue Factor Levels and Salivary Tissue Factor Activities of Periodontitis Patients with and without Cardiovascular Disease. Pathophysiol Haemost Thromb.
http://www.ncbi.nlm.nih.gov/pubmed/21293108
Franchini M, Targher G, Lippi G (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306247
Gavins FN, Russell J, Senchenkova EL, De Almeida Paula L, Damazo AS, Esmon CT, . . . Granger DN(2011) Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood.
http://www.ncbi.nlm.nih.gov/pubmed/21304105
Gidaris D, Economou M, Valeri R, Gombakis N, Athanasiou-Metaxa M (2010) Successful treatment of a spontaneous haemothorax with recombinant factor VIIa in a haemophilic child with inhibitors. Hippokratia 14:289-290.
http://www.ncbi.nlm.nih.gov/pubmed/21311642
Gustafson EK, Elgue G, Hughes RD, Mitry RR, Sanchez J, Haglund U, . . . Nilsson B (2011) The Instant Blood-Mediated Inflammatory Reaction Characterized in Hepatocyte Transplantation. Transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/21289595
Hoffman M, Volovyk Z, Persson E, Gabriel DA, Ezban M, Monroe DM (2011) Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. J Thromb Haemost.
http://www.ncbi.nlm.nih.gov/pubmed/21294824
Jenabali Jahromi B, Karimi M (2011) Long-term follow-up of prophylaxis with recombinant activated factor VII in patients with congenital factor VII deficiency. Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21299748
Jiang W, Kou J, Yuan S, Sun L, Yu B (2011) A Simplified and High-Throughput Chromogenic Assay for Testing Tissue Factor-Dependent Procoagulant Activity. J Biomol Screen.
http://www.ncbi.nlm.nih.gov/pubmed/21310849
Jin Y, Wang M, Niu Z, Xie Y, Xie H, Yang L (2011) [An inherited coagulation factor VII deficiency pedigree caused by homozygous mutation of His348Gln.]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28:10-13.
http://www.ncbi.nlm.nih.gov/pubmed/21287501
Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, Trenk D (2011) High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg.
http://www.ncbi.nlm.nih.gov/pubmed/21295991
Koci J, Dedek T, Havel E, Trlica J (2011) Recombinant Activated Factor VII-"Lifesaving or Surgeon Correcting"? J Trauma 70:523-524.
http://www.ncbi.nlm.nih.gov/pubmed/21307759
Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Osterud B, Sandset PM, Iversen PO (2011) Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul Fibrinolysis.
http://www.ncbi.nlm.nih.gov/pubmed/21297449
Marzano AV, Tedeschi A, Rossio R, Fanoni D, Cugno M (2010) Prothrombotic state in Churg-Strauss syndrome: a case report. J Investig Allergol Clin Immunol 20:616-619.
http://www.ncbi.nlm.nih.gov/pubmed/21314005
Mazer CD, Leong-Poi H, Chhina T, Alfardan Z, Lapierre H, Wang Z, . . . Teitel J (2011) Recombinant factor VIIa affects anastomotic patency of vascular grafts in a rabbit model. J Thorac Cardiovasc Surg.
http://www.ncbi.nlm.nih.gov/pubmed/21281943
Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL (2011) Exposure and safety of higher doses of recombinant factor VIIa >/=250 mug kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21299750
Patel A, Cooper N, Laffan MA (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:574; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306250
Potzsch B, Ivaskevicius V (2011) Haemostasis management of massive bleeding. Hamostaseologie 31:15-20.
http://www.ncbi.nlm.nih.gov/pubmed/21311819
Regnault V, Perret-Guillaume C, Kearney-Schwartz A, Max JP, Labat C, Louis H, . . . Lacolley P (2011) Tissue Factor Pathway Inhibitor: A New Link Among Arterial Stiffness, Pulse Pressure, and Coagulation in Postmenopausal Women. Arterioscler Thromb Vasc Biol.
http://www.ncbi.nlm.nih.gov/pubmed/21293010
Shing CM, Adams MJ, Fassett RG, Coombes JS (2011) Nutritional compounds influence tissue factor expression and inflammation of chronic kidney disease patients in vitro. Nutrition.
http://www.ncbi.nlm.nih.gov/pubmed/21295946
Valentino LA, Cooper DL, Goldstein B (2011) Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia.
http://www.ncbi.nlm.nih.gov/pubmed/21294815
Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, . . . Opal S (2011) Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med.
http://www.ncbi.nlm.nih.gov/pubmed/21297074
Yank V, Stafford RS (2011) Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 364:575; author reply 575-576.
http://www.ncbi.nlm.nih.gov/pubmed/21306248
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
